TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00568776
Drug: ELND005
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELND005 capsules for oral administration at a dose of 2000 mg bid for 78 weeks
Study: NCT00568776
Drug: ELND005
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELND005 capsules for oral administration at a dose of 250 mg bid for 78 weeks
Study: NCT00568776
Drug: ELND005
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELND005 capsules for oral administration at a dose of 1000 mg bid for 78 weeks
Study: NCT00425516
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00277394
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
Study: NCT01964196
Drug: ASP1517
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT01964196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02492737
Drug: AG881
Normalized name: Agenebrutinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
Study: NCT04071236
Drug: Peposertib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03710876
Drug: Celecoxib Oral Product
Normalized name: celecoxib Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg twice daily
Study: NCT01413100
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02128100
Drug: Folfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Oxaliplatin 85 mg/m² for over 2 hours,~* Leucovorin 400n mg/m² for over 2 hours,~* Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion~* Fluorouracil 400 mg/m² as a fast infusion over 15 minutes~* Fluorouracil 2400 mg/m² as a slow infusion over 46 hours
Study: NCT04259801
Drug: NNC0480-0389
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: A single dose of NNC0480-0389, dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of NNC0480-0389, dose increased in each cohort.
Study: NCT04259801
Drug: Placebo (NNC0480-0389)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for NNC0480-0389. Part 1: A single dose of placebo (NNC0480-0389), dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of placebo A, dose increased in each cohort.
Study: NCT04259801
Drug: Placebo (semaglutide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: Single dose of placebo (semaglutide) (0.5 mg). Part 2: Weekly doses of placebo (semaglutide) alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.
Study: NCT03761797
Drug: TRADIANCE® Combination Tablets AP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination
Study: NCT03761797
Drug: TRADIANCE® Combination Tablets BP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination
Study: NCT01096706
Drug: NO clamp
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence or the absence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1.
Study: NCT03792256
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intrathecally (IT)
Study: NCT03792256
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IT
Study: NCT03792256
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravenously (IV)
Study: NCT03792256
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Either prednisone or prednisolone is given PO
Study: NCT03792256
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given intrathecally (IT)
Study: NCT02203552
Drug: minocycline hydrochloride
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg bid given by mouth for 9 weeks
Study: NCT04059770
Drug: single dose of L-AmB
Approvals — FDA: no, EMA: no, PMDA: no
Description: (i) single IV dose of 10 mg/kg of L-AmB on day 1;
Study: NCT04059770
Drug: 2 doses of L-AmB
Approvals — FDA: no, EMA: no, PMDA: no
Description: (ii) IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;
Study: NCT04059770
Drug: 2 weeks of L-AmB
Approvals — FDA: no, EMA: no, PMDA: no
Description: (iii) IV dose of 3 mg/kg of L-AmB for 2 weeks.
Study: NCT01096706
Drug: Combined
Normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Aspirin (600mg stat) is administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study. Intra-arterial Fluconazole is also commenced at the time of the Nitric oxide clamp.~This serves to inhibit the cyclooxygenase, EDHF and NO pathways of endothelial vasodilatation.~Blood samples are taken as per previous arms.
Study: NCT00589693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=solution, route=intravenous. Doripenem pacebo will be administered from Days 1 to 7 in imipenem-cilastatin arm and imipenem-cilastatin placebo will be administered in doripenem arm.
Study: NCT01098383
Drug: Acetyl-Choline Esterase Inhibitors and Choline supplements
Normalized name: Choline esterase
DrugBank: Butyrylcholinesterase (DB06352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil will be used at initial dose of 2.5 mg/day (during the first two weeks), and an increased dose of 5 mg/day (from the 3rd week and on), according to the treatment protocol listed below. The tablets will be taken during breakfast.~AChE inhibitors are considered as potent agents for clinical use in Alzheimer's and Parkinson's dementias (Wevers \& Schroder, 1999) and treatment with these agents was proven to be well-tolerated, safe and effective in these populations. Cholinergic side effects are generally transient, mild and dose-related, and primarily include diarrhea, nausea, and vomiting.~Choline tablets will be taken at daily doses of 250 mg (in children with up to 40 kg body weight) and 500 mg (in children with more than 40 kg body weight), based on half of the adult daily dose.
Study: NCT03872011
Drug: Vitamin C,thiamine,hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (2g) will be diluted in 100ml 0.9%NACL and administered ivd every 6 hours for 5 days or until participant is discharged from the ICU.~Thiamine(200mg) will be diluted in 100ml 0.9%NACL and administered ivd every 12 hours for 5 days or until participant is discharged from the ICU. Hydrocortisone was administered 200 mg/d as a continuous infusion for 5 days or until participant is discharged from the ICU.
Study: NCT03872011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (0.9% NaCl solution) volume to match all components
Study: NCT00645788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg matching placebo powder formulation twice a day for 28 days
Study: NCT02852694
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous methotrexate once weekly 15mg/m2 body surface area (19, 30), with a maximal dose of 25mg/week. Odansetron (Zofran) premedication (4-8mg 1Hour prior to injection) is recommended, folate acid substitution (15mg po, 3 days after Methotrexate injection, for children \<20kg: 1x 5mg) is recommended.
Study: NCT00645788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg matching placebo powder formulation twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
Study: NCT00400153
Drug: Atrovent Respimat (20 mcg)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00400153
Drug: COMBIVENT MDI (36/206 mcg)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01423604
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine starting dose - 2000 mg/m\^2 (1000 mg/m\^2 twice a day (BID)) (NOTE: Frequency of administration may be adjusted during the study.)
Study: NCT01423604
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching ruxolitinib
Study: NCT02241200
Drug: DA3880
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02076230
Drug: [14C] TH-302 (Label 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-labeled TH-302 (Label 1) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
Study: NCT02076230
Drug: [14C] TH-302 (Label 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-labeled TH-302 (Label 2) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
Study: NCT02955810
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02379338
Drug: [18F]Fluortriopride
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive a \[18F\]Fluortriopride PET/CT scan
Study: NCT04275388
Drug: Xiyanping injection
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet /Ritonavir tablet or Alpha-interferon nebulization or Abidor Hydrochloride,
Study: NCT03467386
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01518985
Drug: Bendavia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendavia for infusion Intravenous infusion (0.25mg/kg/hr) for 4 hours
Study: NCT01518985
Drug: Sterile saline (0.9%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline for infusion (0.9%) Intravenous infusion for 4 hours
Study: NCT03924986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match tislelizumab (administered intravenously Q3W)
Study: NCT01787188
Drug: Meloxicam Test Capsules
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01428661
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT00445068
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03740178
Drug: MK-4334
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive MK-4334 capsules administered orally, QD on Days 1-14. Participants will receive an initial loading dose of 120 mg (Day 1), followed by a maintenance dose of 60 mg (Days 2-14). Open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
Study: NCT03740178
Drug: Placebo to MK-4334
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD)will receive placebo capsules matching MK-4334 administered orally, QD on Days 1-14. Participants will also receive open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
Study: NCT03740178
Drug: Donepepzil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive open-label, oral donepezil 10 mg QD on Days 1-14.
Study: NCT01938742
Drug: MF59
Normalized name: vaccine adjuvant emulsion MF59C.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59 adjuvant is an oil-in-water emulsion composed of a small amount of squalene administered with different dosages. Group 1, 2 \& 3 receives 0.7 ml of MF59 Intramuscularly (IM) on days 0 and 21. Group 4 receives MF59 on day 0, Group 5 receives MF59 on Day 21.
Study: NCT04324307
Drug: PD-L1/CTLA4 BsAb
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-L1/CTLA4 BsAb 5mg/kg, iv，Q2W
Study: NCT00597727
Drug: Placebo SLIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid glycerin without peanut which are dosed under the tongue.
Study: NCT00200590
Drug: acetaminophen and morphine
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00200590
Drug: acetaminophen and reduced dosage of prostaglandin
Normalized name: Betagen brand of Betamethasone and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04200781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo granules has the same appearence, weight, shape and color as the experimental drug.
Study: NCT00246441
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment phase will last 16 weeks; dosing will start at 20 mg/day (placebo) and will increase gradually to a maximum dose of 60 mg/day.
Study: NCT00003119
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003119
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02017535
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prozac (fluoxetine capsules, USP) is a selective serotonin reuptake inhibitor for oral administration.
Study: NCT04340427
Drug: TQB3455
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3455 tablets is a small molecule oral drug inhibiting IDH2 mutation.
Study: NCT01393626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets twice daily
Study: NCT00963599
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet taken once daily at bed time for 2 weeks
Study: NCT04976088
Drug: Diclofenac Sodium 140 mg medicated plaster
Normalized name: diclofenac sodium Medicated Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product: Diclofenac Sodium 140 mg medicated plaster, topical application once a day
Study: NCT04976088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: Placebo plaster, topical application once a day.
Study: NCT00390793
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00390793
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01958593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with therapy administered in two blinded experimental sessions. Participants in this group in Stage 1 may take part in Stage 2.
Study: NCT00390793
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or IT
Study: NCT00219544
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01958112
Drug: GSK2141795
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of GSK2141795 is 50 mg orally once per day
Study: NCT00056498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule daily for 16 weeks
Study: NCT03231982
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Machkhan Tab. 8/5 mg + Atacan Tab. 8 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks or Machkhan Tab. 16/5 mg + Atacan Tab. 16 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks
Study: NCT03231982
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atacan Tab. 8 mg + Norvasc Tab. 5 mg + Machkhan Tab.8/5 mg placebo for 8 weeks or Atacan Tab. 16 mg + Norvasc Tab. 5 mg + Machkhan Tab.16/5 mg placebo for 8 weeks
Study: NCT00814801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form= tablet, route= oral use. Corresponding placebo tablets confirmed to be indistinguishable from the galantamine tablets will be administered for 24 weeks.
Study: NCT04432220
Drug: Anticoagulation group(Apixaban group)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5mg twice daily (2.5mg twice daily if meets dose-reduction criteria) for 2 years
Study: NCT03496207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01370434
Drug: PAD combination
Normalized name: PADS,COMBINATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Bortezomib 1.3 mg/m2/d iv on D 1, 4, 8, 11~* Doxorubicin 9 mg/m2/d iv on D 1-4~* Dexamethasone 40mg/d po or iv on D1-4, 8-11
Study: NCT01766310
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: yellow tablet contained 5mg of folic acid, manufactured from the Government Pharmaceutical Organization, Ministry of Public Health, Thailand
Study: NCT01766310
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar tablet manufactured to mimic folic acid tablet
Study: NCT03224117
Drug: DWJ211
Approvals — FDA: no, EMA: no, PMDA: no
Description: inject the Drug into submental fat via subcutaneous
Study: NCT03224117
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: inject the Drug into submental fat via subcutaneous
Study: NCT02996617
Drug: rhG-CSF regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients weren't preventive use of rhG-CSF.If their WBC≤1×10\^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10\^ 9/L.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
Study: NCT02996617
Drug: Pegylated rhG-CSF regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
Study: NCT00719758
Drug: TRK-100STP (BERASUS LA)
Normalized name: PRUNUS CERASUS FLOWER
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03310320
Drug: AZD0284 oral solution 2.5 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks
Study: NCT03310320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for AZD0284 oral solution, twice daily for 4 weeks
Study: NCT01256398
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04526951
Drug: One tablet of Acetylsalicylic Acid and one dose of IV placebo
Normalized name: codeine and acetylsalicylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Acetylsalisylic acid
Study: NCT01256398
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT01256398
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01256398
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, IV, or PO
Study: NCT03216681
Drug: Hoat Huyet Nhat Nhat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally twice a day, 2 tablets each time, for 45 days.
Study: NCT00061945
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00061945
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, IV, and PO
Study: NCT00061945
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00061945
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV and PO
Study: NCT04491643
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At a dosage of 10 mg/day
Study: NCT00086931
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral dose escalating, twice daily.
Study: NCT00567346
Drug: Oralgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive drops of grass pollen immunotherapy sublingually